NCT03977935

Brief Summary

The aim of this study is to evaluate the clinical application of the second-generation MCCG with higher image resolution and frame rate for upper gastrointestinal tract compared with the first-generation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 10, 2019

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

June 3, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 6, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 18, 2019

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2019

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

October 27, 2020

Completed
Last Updated

October 27, 2020

Status Verified

June 1, 2019

Enrollment Period

2 months

First QC Date

June 3, 2019

Results QC Date

July 27, 2020

Last Update Submit

October 6, 2020

Conditions

Keywords

SG-MCCGZ-line visualizationImage qualityGastric examination timeManipulation performance

Outcome Measures

Primary Outcomes (1)

  • Circumferential Visualization of the Z-line

    Circumferential visualization of the Z-line is defined by quadrants as follows: less than 2 quadrants (\< 50%) of the Z line observed; at least 2 quadrants (50%-75%) observed; at least 3 quadrants (\>75%) observed; and entire Z line (100%) observed.

    Through end of examination, up to 30 minutes

Secondary Outcomes (10)

  • Detection Rate of Duodenal Papilla

    up to 2 days after the examination

  • Gastric Examination Time (GET)

    Through end of examination, up to 30 minutes

  • Manipulation Performance Score of the MCCG

    up to 10 minutes after the examination

  • Image Quality Score (Mainly Focus on Clarity)

    up to 30 minutes after the examination

  • The Number of Images Captured for Esophagus and Z-line

    up to 30 minutes after the examination

  • +5 more secondary outcomes

Study Arms (2)

The first-generation MCCG group

NO INTERVENTION

The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the "360-degree automatic scanning" mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the "small-bowel mode". The magnetic steering time for passing through the pylorus was not allowed more than 15 min.

The second-generation MCCG group

EXPERIMENTAL

All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.

Device: the second-generation MCCG

Interventions

Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).

The second-generation MCCG group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • With or without gastrointestinal complaints
  • Scheduled to undergo a capsule endoscopy for both stomach and small bowel
  • Signed the informed consents before joining this study

You may not qualify if:

  • Dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal stenosis, overt gastrointestinal bleeding, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy
  • Refused abdominal surgery to take out the capsule in case of capsule retention
  • Implanted pacemaker, except the pacemaker is compatible with MRI
  • Other implanted electromedical devices or magnetic metal foreign bodies
  • Pregnancy or suspected pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changhai Hospital

Shanghai, 200433, China

Location

Related Publications (1)

  • Jiang B, Qian YY, Pan J, Jiang X, Wang YC, Zhu JH, Zou WB, Zhou W, Li ZS, Liao Z. Second-generation magnetically controlled capsule gastroscopy with improved image resolution and frame rate: a randomized controlled clinical trial (with video). Gastrointest Endosc. 2020 Jun;91(6):1379-1387. doi: 10.1016/j.gie.2020.01.027. Epub 2020 Jan 22.

Results Point of Contact

Title
Investigator of Clinical Trials
Organization
Changhai Hospital

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

June 3, 2019

First Posted

June 6, 2019

Study Start

May 10, 2019

Primary Completion

July 18, 2019

Study Completion

July 25, 2019

Last Updated

October 27, 2020

Results First Posted

October 27, 2020

Record last verified: 2019-06

Locations